Trials / Unknown
UnknownNCT02525172
Immune Modulation Therapy for Pompe Disease
Immune Modulation Therapy for ERT-naïve or ERT-treated Pompe Disease Patients
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- Sponsor
- National Taiwan University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers after treatment with immune modulation therapy in patients of Pompe disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | |
| DRUG | intravenous immune globulin | |
| DRUG | Bortezomib | |
| DRUG | Methotrexate |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2020-07-01
- Completion
- 2020-07-01
- First posted
- 2015-08-17
- Last updated
- 2016-04-15
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT02525172. Inclusion in this directory is not an endorsement.